Fecal microbiota transplantation (FMT) is a promising treatment for microbiota dysbiosis and may provide metabolic benefits for obesity. However, its mechanisms and variability in clinical outcomes remain poorly understood. This 12-week multicenter, single-arm study evaluated the efficacy of FMT for weight loss and explored the role of donor-derived microbial engraftment and functional shifts in mediating weight loss among overweight and obese individuals. Twenty-three participants (body mass index ≥24 kg/m²) without diabetes received three biweekly FMT sessions via a nasojejunal tube. Fecal samples from participants and donors were analyzed using metagenomic sequencing. By week 12, 52% of participants were classified as responders, achieving significant weight loss of ≥5% from baseline, with an average weight loss of 7.98 ± 2.69 kg ( P < 0.001). In contrast, non-responders lost 2.90 ± 1.89 kg ( P < 0.001). Responders exhibited a significantly higher proportion of donor-derived microbial strains post-FMT compared to non-responders (37.8% vs 15.2%, P = 0.020). Notably, key taxa, including Phascolarctobacterium ( P = 0.034) and Acidaminococcaceae ( P = 0.012), increased significantly in abundance in responders post-FMT, indicating successful microbial engraftment as a critical determinant of therapeutic success. These findings suggest that FMT is a viable intervention for weight loss in obese individuals. Successful donor-derived microbial engraftment strongly correlates with weight loss efficacy, highlighting the potential of microbiota-targeted therapies in obesity management and providing insights into the mechanisms underlying FMT outcomes. IMPORTANCE: Prior research indicates that fecal microbiota transplantation (FMT) is a promising treatment for diseases related to microbiota imbalance, potentially providing metabolic benefits for obesity. However, the specific role of donor-derived microbial engraftment in driving clinical efficacy has remained unclear. In this study, we evaluated the efficacy of FMT in promoting weight loss and explored the role of donor-derived bacterial strains in this process. Our findings demonstrate that the successful engraftment of specific donor-derived taxa, such as Phascolarctobacterium and Acidaminococcaceae , is strongly associated with significant weight loss. This highlights the critical interplay between donor microbiota and recipient gut environment. These findings underscore the potential of microbiota-targeted therapies as a novel strategy for obesity management. CLINICAL TRIALS: This study is registered with the Chinese Clinical Trial Registry as ChiCTR1900024760 .
29 August 2026 in European Journal of Clinical Nutrition
Through fasting and feeding (both in vivo and in vitro), nutrient availability fluctuates over time. Pancreatic β-cells must respond to nutrients not only by regulated insulin secretion but also by insulin synthesis, which depends upon proinsulin. β-cells respond biosynthetically to glucose, but little is known about amino acids as regulators of proinsulin levels. We find that in INS1E (rat) β-cells, isolated murine islets, and isolated human islets—even in the presence of abundant glucose, proinsulin levels remain sensitive to reduced availability of other nutrients contained in β-cell/islet bathing medium. A low proinsulin level upon in vitro fasting is accompanied by diminished ribosomal phospho-S6 and phospho-eIF4E-BP1 plus increased phospho-eIF2α, reversed upon re-feeding. Even as extracellular glucose levels remained steady, INS1E cells consumed the majority of extracellular glutamine and serine (measured by mass spectrometry); concurrently, six nonessential amino acids (most notably proline and alanine, plus glutamic and aspartic acid) were actually exported from cells to media. Proinsulin suppression in response to amino acid limitation appears to be β-cell-autonomous, is linked to proinsulin biosynthesis, and is ameliorated upon GCN2 inhibition in INS1E cells. Upon re-feeding amino acid-containing medium, the mTORC1 inhibitor rapamycin fully suppressed phospho-S6 but did not block the recovery of proinsulin levels, whereas Torin1 inhibition of mTOR inhibited the amino acid-dependent increase in proinsulin biosynthesis. Altogether, these data indicate that inadequate amino acid-triggered β-cell signaling can blunt the proinsulin biosynthetic response, contributing to insulin deficiency—a finding that has potential relevance to the pathogenesis of malnutrition-related diabetes.